Health
FDA approves first treatment for a rare genetic disorder – News-Medical.Net
Today, the U.S. Food and Drug Administration approved Oxlumo (lumasiran) as the first treatment for primary hyperoxaluria type 1 (PH1), a rare genetic disorder.
Reviewed by Emily Henderson, B.Sc.Nov 23 2020
Today, the U.S. Food and Drug Administration approved Oxlumo (lumasiran) as the first treatment for primary hyperoxaluria type 1 (PH1), a rare genetic disorder. This approval is a cumulation of the work of experts and community members coordinated by the Oxalosis & Hyperoxaluria Foundation and the Kidney Health Initiative.
The approval of Oxlumo represents a great triumph of community involvement to address a rare disease. It is a result of input…
-
Noosa News14 hours agoPerth Royal Show vendors upset by price hikes, say crowds are down in 2025
-
General8 hours agoCampers evacuated, residents on alert as Moreton Island bushfire intensifies
-
Business16 hours agoBell Potter names the best ASX shares to buy in October
-
General15 hours agoTasmanian woman drowns on day 5 of multi-day Franklin River rafting trip